Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02455011 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by REMD Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT02455011 is a Phase 1 study that has completed, run by REMD Biotherapeutics. The registered enrollment target is 75 participants.
The verdict
NCT02455011, a Phase 1 study, has completed, sponsored by REMD Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled, double-blind, dose escalation study to evaluate safety, tolerability, PK and PD of single and repeated SC doses of REMD-477 in Type 2 diabetic subjects. The study will be conducted at multiple sites in the United States and will enroll approximately 102 subjects with Type 2 diabetes who are either treatment-naïve, controlled with diet and exercise or treated with oral antidiabetic medications.
Interventions
- BIOLOGICAL REMD-477
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02455011
The ClinicalTrials.gov registry entry for NCT02455011 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is REMD Biotherapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which REMD-477 is the first listed.
NCT02455011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02455011 about?
NCT02455011 is a clinical study titled "Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus". This is a randomized, placebo-controlled, double-blind, dose escalation study to evaluate safety, tolerability, PK and PD of single and repeated SC doses of REMD-477 in Type 2 diabetic subjects. The study will be conducted at multiple sites in the United States and will enroll approximately 102 subj...
What is the current status of trial NCT02455011?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2015-09. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02455011?
The interventions under investigation include: REMD-477 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02455011?
This trial is sponsored by REMD Biotherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.